Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant.

Tai, Wanbo; Chai, Benjie; Feng, Shengyong; Zhuang, Xinyu; Ma, Jun; Pang, Mujia; Pan, Lin; Yang, Zi; Tian, Mingyao; Cheng, Gong

Tai, Wanbo; Chai, Benjie; Feng, Shengyong; Zhuang, Xinyu; Ma, Jun; Pang, Mujia; Pan, Lin; Yang, Zi; Tian, Mingyao; Cheng, Gong.

Affiliation

Tai W; Institute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, Guangdong, China.
Chai B; Tsinghua-Peking Joint Center for Life Sciences, School of Medicine, Tsinghua University, Beijing, China.
Feng S; Tsinghua-Peking Joint Center for Life Sciences, School of Medicine, Tsinghua University, Beijing, China.
Zhuang X; Tsinghua-Peking Joint Center for Life Sciences, School of Medicine, Tsinghua University, Beijing, China.
Ma J; Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Pang M; Institute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, Guangdong, China.
Pan L; Institute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, Guangdong, China.
Yang Z; Institute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, Guangdong, China.
Tian M; Tsinghua-Peking Joint Center for Life Sciences, School of Medicine, Tsinghua University, Beijing, China.
Cheng G; Tsinghua-Peking Joint Center for Life Sciences, School of Medicine, Tsinghua University, Beijing, China.

Signal Transduct Target Ther ; 7(1): 173, 2022 06 01.

Article in En | MEDLINE | ID: mdl-35650183

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Viral Vaccines / Nanoparticles / COVID-19 Limits: Humans Language: En Journal: Signal Transduct Target Ther Year: 2022 Document type: Article Affiliation country: China

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google